Open AccessImmunotherapy in HER2-Positive Breast Cancer: A Systematic Review
Author(s) -
Anastasios Kyriazoglou,
Maria Kaparelou,
G. Goumas,
Michael Liontos,
Roubini Zakopoulou,
Εleni Zografos,
Anna Zygogianni,
Meletios A. Dimopoulos,
Flora Zagouri
Publication year - 2021
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000514860
Subject(s) - medicine , breast cancer , immunotherapy , oncology , trastuzumab , cancer , gynecology
The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors in HER2-positive Breast cancer is a concept supported by the reported biological and preclinical data. Methods: We conducted a systematic review of the current literature involving immune checkpoint inhibitors alone or in combination with targeted therapies or chemotherapy finalized or running in HER2-positive breast cancer. Results: Twelve clinical trials and 2 case reports were identified in our study. Conclusion: The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer.